Trending stocks today
Royalty Pharma plc (RPRX-Q)
NASDAQ:RPRX
30.03
0.04
(0.13%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
This summary was created by AI, based on 1 opinions in the last 12 months.
Royalty Pharma plc (RPRX-Q) is a company that partners with pharma companies like Bristol-Myers to fund development in exchange for collecting royalties. It has demonstrated financial strength by paying a good dividend with a low payout ratio. The stock is currently trading at attractive valuations with a 10x earnings, under 2x book, and supports a solid 17% ROE. The company's portfolio also experienced strong growth this year, making it an appealing investment choice with a potential upside of 28%. Overall, Royalty Pharma is positioned as a financially sound company with strong growth prospects.
$25.650
Unknown
- «
- ‹
- 1
- ›
- »
Royalty Pharma plc(RPRX-Q) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Royalty Pharma plc(RPRX-Q) Frequently Asked Questions
What is Royalty Pharma plc stock symbol?
Royalty Pharma plc is a American stock, trading under the symbol RPRX-Q on the NASDAQ (RPRX). It is usually referred to as NASDAQ:RPRX or RPRX-Q
Is Royalty Pharma plc a buy or a sell?
In the last year, there was no coverage of Royalty Pharma plc published on Stockchase.
Is Royalty Pharma plc a good investment or a top pick?
Royalty Pharma plc was recommended as a Top Pick by on . Read the latest stock experts ratings for Royalty Pharma plc.
Why is Royalty Pharma plc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Royalty Pharma plc worth watching?
0 stock analysts on Stockchase covered Royalty Pharma plc In the last year. It is a trending stock that is worth watching.
What is Royalty Pharma plc stock price?
On 2025-01-14, Royalty Pharma plc (RPRX-Q) stock closed at a price of $30.03.
RPRX partners with pharma companies like Bristol-Myers to help fund development in exchange for collecting royalties. It pays a good dividend, backed by a payout ratio under 33% of cash flow. It trades at 10x earnings, under 2x book and supports a 17% ROE. Its portfolio grew by 15% this year. We recommend setting a stop-loss at $22, looking to achieve $33 -- upside potential of 28%. Yield 3.2%
(Analysts’ price target is $41.53)